New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5080-5087

  Blair, Wade S ^b,c   Cao, Joan ^b   Fok Seang, Juin ^a   Griffin, Paul ^a   Isaacson, Jason ^b   Jackson, R Lynn ^b,d   Murray, Edward ^a   Patick, Amy K ^b,e   Peng, Qinghai ^b   Perros, Manos ^a   Pickford, Chris ^a   Wu, Hua ^b   Butler, Scott L ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

^c GENENTECH INC   (United States)

^d Nanogen Inc USA   (United States)

^e Adamas Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (4 TERT BUTYLPHENYL) 2 (2,3 DIHYDRO 1H INDEN 2 YLAMINO)ETHYL] 3 (TRIFLUOROMETHYL)PYRIDIN 2(1H) ONE; 3 O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID; ANTIVIRUS AGENT; EFAVIRENZ; NELFINAVIR; PF 46396; PROTEIN P25; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRION; VIRUS CAPSID; VIRUS CORE; VIRUS PARTICLE; VIRUS REPLICATION;

ANTI-HIV AGENTS; BLOTTING, WESTERN; CAPSID PROTEINS; CELL LINE; CELLS, CULTURED; HELA CELLS; HIV-1; HUMANS; MOLECULAR STRUCTURE; VIRION;

EID: 71249123121     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00759-09     Document Type: Article

References (28)

1. Adamson, C. S., S. D. Ablan, I. Boeras, R. Goila-Gaur, F. Soheilian, K. Nagashima, F. Li, K. Salzwedel, M. Sakalian, C. T. Wild, and E. O. Freed. 2006. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (bevirimat). J. Virol. 80:10957-10971.
2. Aiken, C., and C. H. Chen. 2005. Betulinic acid derivatives as HIV-1 antivirals. Trends Mol. Med. 11:31-36.
3. Baichwal, V., H. Austin, B. Brown, R. McKinnon, K. Yager, V. Kumar, D. Gerrish, M. Anderson, and R. Carlson. 2009. Anti-viral characterization in vitro of a novel maturation inhibitor, MPC-9055, poster 561. 16th Conf. Retrovir. Opport. Infect., Montreal, Canada.
4. Beelen, A., J. Otto, M. Fidler, E. Sanguinetti, P. Smiley, A. Balch, M. Medlock, M. Jackson, and E. Swabb. 2009. Phase-1 single ascending oral dose study of the safety, tolerability, and pharmacokinetics of a novel HIV-1 maturation inhibitor in HIV negative, healthy volunteers, poster 570. 16th Conf. Retrovir. Opport. Infect., Montreal, Canada.
5. Blair, W. S., J. Cao, L. Jackson, J. Jimenez, Q. Peng, H. Wu, J. Isaacson, S. L. Butler, A. Chu, J. Graham, A.-M. Malfait, M. Tortorella, and A. K. Patick. 2007. Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing. Antimicrob. Agents Chemother. 51:3554-3561.
6. Blair, W. S., J. Isaacson, X. Li, J. Cao, Q. Peng, G. F. Z. Kong, and A. K. Patick. 2005. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antivir. Res. 65:107-116.
7. Buckheit, R. W., Jr., and R. Swanstrom. 1991. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res. Hum. Retrovir. 7:295-302.
8. Cao, J., J. Isaacson, A. K. Patick, and W. S. Blair. 2005. High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target. Antimicrob. Agents Chemother. 49:3833-3841.
9. Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
10. Gerrish, D., I. C. Kim, D. V. Kumar, H. Austin, J. E. Garrus, V. Baichwal, M. Saunders, R. S. McKinnon, M. B. Anderson, R. Carlson, E. Arranz- Plaza, and K. M. Yager. 2008. Triterpene based compounds with potent anti-maturation activity against HIV-1. Bioorg. Med. Chem. Lett. 18:6377-6380.
11. Gulick, R. M., J. Lalezari, J. Goodrich, N. Clumeck, E. DeJesus, A. Horban, J. Nadler, B. Clotet, A. Karlsson, M. Wohlfeiler, J. B. Montana, M. McHale, J. Sullivan, C. Ridgway, S. Felstead, M. W. Dunne, E. van der Ryst, and H. Mayer. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429-1441.
12. Huang, L., X. Yuan, C. Aiken, and C. H. Chen. 2004. Bifunctional antihuman immunodeficiency virus type 1 small molecules with two novel mechanisms of action. Antimicrob. Agents Chemother. 48:663-665.
13. Kashiwada, Y., F. Hashimoto, L. M. Cosentino, C. H. Chen, P. E. Garrett, and K. H. Lee. 1996. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J. Med. Chem. 39:1016-1017.
14. Li, F., R. Goila-Gaur, K. Salzwedel, N. R. Kilgore, M. Reddick, C. Matallana, A. Castillo, D. Zoumplis, D. E. Martin, J. M. Orenstein, G. P. Allaway, E. O. Freed, and C. T. Wild. 2003. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. USA 100:13555-13560.
15. Li, F., D. Zoumplis, C. Matallana, N. R. Kilgore, M. Reddick, A. S. Yunus, C. S. Adamson, K. Salzwedel, D. E. Martin, G. P. Allaway, E. O. Freed, and C. T. Wild. 2006. Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology 356:217-224. (Pubitemid 44750029)
16. Lipinski, C. A., F. Lombardo, B. W. Dominy, and P. J. Feeney. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23: 3-25.
17. Martin, D., J. Jacobson, D. Schurmann, E. Osswald, J. Doto, C. Wild, and G. P. Allaway. 2005. PA-457, the first-in-class maturation inhibitor, exhibits antiviral activity following a single oral dose in HIV-1 infected patients, oral presentation 159. 12th Conf. Retrovir. Opport. Infect., Boston, MA.
18. Pettit, S., J. Lindquist, A. Kaplan, and R. Swanstrom. 2005. Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology 2:66. (Pubitemid 41631830)
19. Sakalian, M., C. P. McMurtrey, F. J. Deeg, C. W. Maloy, F. Li, C. T. Wild, and K. Salzwedel. 2006. 3-O-(3′,3′-Dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro. J. Virol. 80:5716-5722. (Pubitemid 43849149)
20. Salzwedel, K., F. Hamy, S. Luouvel, M. Sakalian, M. Reddick, C. Finnegan, D. Martin, S. McCallister, T. Klimkait, and G. P. Allaway. 2009. Susceptibility of diverse HIV-1 patient isolates to the maturation inhibitor, bevirimat, is determined by clade-specific polymorphisms in Gag CA-SP1, poster 635. 16th Conf. Retrovir. Opport. Infect., Montreal, Canada.
21. Salzwedel, K., D. E. Martin, and M. Sakalian. 2007. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 9:162-172. (Pubitemid 350001487)
22. Smith, P. F., A. Ogundele, A. Forrest, J. Wilton, K. Salzwedel, J. Doto, G. P. Allaway, and D. E. Martin. 2007. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-O-(3′3′- dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob. Agents Chemother. 51:3574-3581.
23. Steigbigel, R. T., D. A. Cooper, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohmaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, B. Y. Nguyen, and H. Teppler. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
24. Van Baelen, K., K. Salzwedel, E. Rondelez, V. Van Eygen, S. De Vos, A. Verheyen, K. Steegen, Y. Verlinden, G. P. Allaway, and L. J. Stuyver. 2009. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob. Agents Chemother. 53:2185-2188.
25. Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
26. Wright, E. R., J. B. Schooler, H. J. Ding, C. Kieffer, C. Fillmore, W. I. Sundquist, and G. J. Jensen. 2007. Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. EMBO J. 26:2218-2226.
27. Zhou, J., C. H. Chen, and C. Aiken. 2004. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3′,3′-dimethylsuccinyl}- betulinic acid. Retrovirology 1:15. (Pubitemid 39130580)
28. Zhou, J., X. Yuan, D. Dismuke, B. M. Forshey, C. Lundquist, K. H. Lee, C. Aiken, and C. H. Chen. 2004. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J. Virol. 78:922-929. (Pubitemid 38067613)